Over the next several months, the National Institute of Allergy and Infectious Diseases expects to enroll up to 1,500 adult COVID-19 hospital patients who require supplemental oxygen in a global clinical trial that aims to determine whether baricitinib or dexamethasone is more effective at preventing mechanical ventilation or death when administered with remdesivir. One group of participants will receive dexamethasone and remdesivir, and another group will receive remdesivir and baricitinib.

Related News Articles

Headline
The public health emergency will likely remain in place through 2021, and the administration will give states 60 days’ notice before it decides to terminate…
Headline
The Food and Drug Administration Jan. 21 reissued emergency use authorizations for 10 systems authorized to decontaminate certain N95 respirators used by…
Headline
Pfizer Inc. has completed enrolling children aged 12 to 15 in a COVID-19 vaccine study, the drug maker confirmed Friday.  Pfizer said the Phase 3…
Chairperson's File
This year, I look forward to continuing AHA’s Leadership Rounds, short conversations on trending topics with health care leaders from around the country.…
Headline
As COVID-19 surges continue, lessons learned by health systems large and small reveal the importance of teamwork, communication, flexibility, preparation and…
Headline
The Centers for Disease Control and Prevention today reported 10 cases of anaphylaxis, a life-threatening allergic reaction, among the more than 4 million…